Skip to main content

LeMaitre Vascular, Inc.

corporate_fare Company Profile

LeMaitre Vascular, Inc.

LMAT·NASDAQ·Industrial Applications And Services·CIK 0001158895

LEMAITRE VASCULAR INC is a global provider of medical devices and human tissue cryopreservation services primarily used in treating peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices for vascular surgeons and, to a lesser extent, cardiac surgeons, general surgeons, and neurosurgeons. Its diverse portfolio includes brand name products for use in arteries and veins, which are recognized by vascular surgeons. LEMAITRE VASCULAR INC's main product offerings are sold globally, with primary markets in the United States, Europe, Canada, and Asia Pacific. The company estimates the annual worldwide market for peripheral vascular devices exceeds $9 billion, with the market for its specific products estimated at approximately $1 billion. Sales are primarily conducted through a direct sales force. The company's worldwide headquarters is in Burlington, Massachusetts, with a North American sales office in Vaughan, Canada. Its European headquarters is in Sulzbach, Germany, supported by sales offices in Milan, Italy; Madrid, Spain; Hereford, England; Dublin, Ireland; Maisons-Alfort, France; and Glattbrugg, Switzerland. The Asia Pacific headquarters is in Singapore, with sales offices in Tokyo, Japan; Shanghai, China; Docklands, Australia; Seoul, Korea; and Bangkok, Thailand. For the year ended December 31, 2025, approximately 95% of net sales came from territories with direct sales representatives. Products are also sold through distributors in other countries. As of December 31, 2025, the sales force included 160 sales representatives and export managers across North America, Europe, and Asia Pacific. Peripheral vascular disease affects over 200 million people worldwide.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 16 items for LMAT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for LMAT spans 10-Q, 8-K, 4, 144.

Recent high-impact activity:

  • LeMaitre Q3: Sales Up 11% but Gross Margin Slips 360 bps; $17M B. Braun Deal Closed
  • LeMaitre Lifts 2026 Outlook and Buys B. Braun Vascular Assets for $19.2M
  • LeMaitre Q3 Sales Up 11% to $68.0M; EPS $0.65, FY26 Guidance $2.77-$2.82
  • LeMaitre Vascular Posts $15M Third-Quarter Net Income
  • LeMaitre Vascular President David Roberts to Retire Dec 31; Will Stay on Board

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$249.6M
Net Income
$57.73M
Diluted EPS
$2.52
Op. Cash Flow
$81.25M
Free Cash Flow
$74.47M
Gross Profit
$178.54M
Operating Income
$67.91M
Cash & Equivalents
$28.24M
Total Debt
$168.65M
Debt / Equity
0.43×
Net Margin
23.1%
Shares Outstanding
22.77M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073360

Short Interest & Short Volume

6.57 days to cover

FINRA reported short interest of 1,776,179 shares in LMAT as of the October 15, 2026 settlement, a 2.1% increase from the prior period — about 6.6 days to cover at its recent average daily volume. On November 6, 2026, 51.3% of LMAT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,776,179 shares as of October 15, 2026
Change vs prior period▲ 2.1%
Days to cover6.57 at avg daily volume of 270,391
Daily short volume (FINRA facilities)51.3% of 136,124 shares on November 6, 2026
5-day average short volume50.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$80.89
52-week range · as of 2026-11-05 $78.22 – $118.01
Market cap
$1.85B
Volume
326.4K (1.1× avg)
3-mo avg 292.1K
Live data · 2026-11-08 10:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LMAT - Latest Insights

LMAT
Nov 05, 2026, 6:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $80.60
Real-time Price: $80.89 info
Change: +$0.290 (+0.36%) info
Market Cap: $1.85B info
LMAT
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $78.48
Real-time Price: $80.89 info
Change: +$2.41 (+3%) info
Market Cap: $1.85B info
LMAT
Nov 04, 2026, 4:40 PM EST
Filing Type: 8-K
Importance Score:
7
Updated Nov 4, 5:19 PM ET — LeMaitre Vascular's Q3 sales rose 11% to $67.97 mln, slightly beating the $67.39 mln consensus of 8 analysts.
Price at Filing: $76.11
Real-time Price: $80.89 info
Change: +$4.78 (+6%) info
Market Cap: $1.85B info
LMAT
Nov 04, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $87.92
Real-time Price: $80.89 info
Change: -$7.03 (-8%) info
Market Cap: $1.85B info
LMAT
Oct 15, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $83.16
Real-time Price: $80.89 info
Change: -$2.27 (-3%) info
Market Cap: $1.85B info
LMAT
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $81.45
Real-time Price: $80.89 info
Change: -$0.560 (-0.69%) info
Market Cap: $1.85B info
LMAT
Aug 05, 2026, 6:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $103.60
Real-time Price: $80.89 info
Change: -$22.71 (-22%) info
Market Cap: $1.85B info
LMAT
Aug 04, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $92.00
Real-time Price: $80.89 info
Change: -$11.11 (-12%) info
Market Cap: $1.85B info
LMAT
Aug 04, 2026, 4:39 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $92.25
Real-time Price: $80.89 info
Change: -$11.36 (-12%) info
Market Cap: $1.85B info
LMAT
May 11, 2026, 6:22 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $101.74
Real-time Price: $80.89 info
Change: -$20.85 (-20%) info
Market Cap: $1.85B info
LMAT
May 06, 2026, 6:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $112.00
Real-time Price: $80.89 info
Change: -$31.11 (-28%) info
Market Cap: $1.85B info
LMAT
May 05, 2026, 4:34 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $112.00
Real-time Price: $80.89 info
Change: -$31.11 (-28%) info
Market Cap: $1.85B info
LMAT
May 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $112.00
Real-time Price: $80.89 info
Change: -$31.11 (-28%) info
Market Cap: $1.85B info
LMAT
Mar 02, 2026, 12:06 PM EST
Filing Type: 144
Importance Score:
8
Price at Filing: $109.18
Real-time Price: $80.89 info
Change: -$28.29 (-26%) info
Market Cap: $1.85B info
LMAT
Feb 26, 2026, 7:01 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $91.38
Real-time Price: $80.89 info
Change: -$10.49 (-11%) info
Market Cap: $1.85B info
LMAT
Feb 25, 2026, 4:54 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $91.38
Real-time Price: $80.89 info
Change: -$10.49 (-11%) info
Market Cap: $1.85B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets